Archives of Dermatological Research最新文献

{"title":"Correction: Assessment of miR-19b-3p, miR-182-5p, and miR-155-5p expression and its relationship with alopecia areata severity","authors":"Ahmed Ibrahim AbdElneam, Mohammed Saleh Al-Dhubaibi, Saleh Salem Bahaj, Ghada Farouk Mohammed, Lina Mohammed Atef","doi":"10.1007/s00403-025-04240-9","DOIUrl":"10.1007/s00403-025-04240-9","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143845808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ligilactobacillus salivarius Lac45 inhibits MRSA and suppresses inflammation in human keratinocyte","authors":"Punploy Klawkla,&nbsp;Hung Gia Tran,&nbsp;Poorichaya Somparn,&nbsp;Somying Tumwasorn,&nbsp;Tanittha Chatsuwan,&nbsp;Jongkonnee Wongpiyabovorn","doi":"10.1007/s00403-025-04227-6","DOIUrl":"10.1007/s00403-025-04227-6","url":null,"abstract":"<div><p>Dysbiosis, an imbalance in skin microflora, is a key contributor to inflammatory skin conditions, including atopic dermatitis (AD), seborrheic dermatitis (SD), and psoriasis. In AD, <i>Staphylococcus aureus</i> colonization of skin lesions is prevalent approximately 70% of cases, with disease severity positively correlating with bacterial presence. Moreover, methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) is found in 10–30% of AD skin lesions, highlighting the need for novel therapeutic strategies that target both microbial imbalance and inflammation. This study evaluates <i>Ligilactobacillus salivarius</i> Lac45 (LS-Lac45), a breast milk-derived bacterial strain, for its antimicrobial and anti-inflammatory potential in dermatology. We assessed its antimicrobial activity against MRSA using an agar disk-diffusion assay and its anti-inflammatory effects in a peptidoglycan (PGN)-induced inflammation model in HaCaT keratinocytes. To elucidate its mechanisms of action, mass spectrometry was used to analyze protein expression changes in LS-Lac45-treated keratinocytes. Our results demonstrate that live LS-Lac45 effectively inhibits MRSA growth. Additionally, heat-killed LS-Lac45 significantly reduces PGN-induced production of pro-inflammatory cytokines IL-6, IL-8, and TNF-α. Proteomic analysis further identifies LS-Lac45-mediated modulation of immune-related proteins, including heat shock protein 60, metallothionein 2A, and antioxidant-1, suggesting a role in inflammatory regulation. These findings highlight LS-Lac45 as a candidate for managing MRSA-associated inflammatory skin conditions, particularly AD. While this study provides key insights into its antimicrobial and immunomodulatory properties, further research is needed to evaluate its probiotic characteristics and clinical applicability in dermatology.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143840516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous epidermal growth factor receptor expression (EGFR) and soluble EGFR levels are elevated in patients with pemphigus vulgaris: a longitudinal study","authors":"Kanmani Indra Couppoussamy,&nbsp;Medha Rajappa,&nbsp;Laxmisha Chandrashekar","doi":"10.1007/s00403-025-04207-w","DOIUrl":"10.1007/s00403-025-04207-w","url":null,"abstract":"<div><p>Epidermal Growth Factor Receptor (EGFR) signalling is thought to be involved in the pathogenesis of pemphigus vulgaris. The objective was to assess the cutaneous EGFR mRNA expression and serum soluble EGFR (sEGFR) levels among Pemphigus patients in comparison to the healthy controls. This was a cross-sectional study with a longitudinal follow up. Thirty patients with pemphigus vulgaris and 30 controls were recruited. We measured cutaneous EGFR mRNA expression and sEGFR serum levels in pemphigus vulgaris patients at baseline, at three- and six-months following treatment. There was a significant (<i>p</i> = 0.007) difference of the EGFR mRNA fold expression between cases (3.07 (IQR (Interquartile range) 0.76 to 13.20)) at baseline as compared to the controls (1.005 (Interquartile range (IQR) 0.63 to 2.30)). The median sEGFR levels were significantly (<i>p</i> &lt; 0.0001) higher in the cases (4.33 ng/ml (IQR 3.01 ng/ml to 9.33 ng/ml)) compared to controls (1.52 ng/ml (IQR 0.79 ng/ml to 2.75 ng/ml)) at the baseline. There was a significant positive correlations of EGFR mRNA expression (<i>r</i> = 0.47) and sEGFR levels (<i>r</i> = 0.46) with pemphigus disease activity. The limitation of the study was smaller sample size. EGFR gene expression and sEGFR levels are significantly increased in pemphigus vulgaris. They significantly correlate with disease activity and decrease with treatment.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143845726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life, sleep, and psychological well-being in chronic spontaneous urticaria patients receiving omalizumab: a case–control study","authors":"Mustafa Esen,&nbsp;Abdullah Demirbaş,&nbsp;Esin Diremsizoglu","doi":"10.1007/s00403-025-04231-w","DOIUrl":"10.1007/s00403-025-04231-w","url":null,"abstract":"<div><p>Chronic spontaneous urticaria (CSU) impacts both physical and mental well-being, causing distress and sleep disturbances. While omalizumab reduces disease activity, its effects on mental health and quality of life remain unclear. This study assesses the psychosocial burden and sleep disturbances in CSU patients receiving omalizumab compared to healthy controls and explores their relationship with disease parameters. This case––control study included 210 CSU patients receiving omalizumab for at least three months and 210 age- and sex-matched healthy controls. Disease severity was assessed using the Urticaria Activity Score over 7 Days (UAS7) and Urticaria Control Test (UCT), while quality of life was evaluated with the Chronic Urticaria Quality of Life Questionnaire (CU-Q₂oL). Psychological distress and sleep disturbances were measured using validated scales, including the Perceived Stress Scale (PSS), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS). CSU patients had significantly higher scores for perceived stress, depression, anxiety, and daytime sleepiness compared to controls (p &lt; 0.001). Patients with a good response to omalizumab also showed significantly higher psychological distress and poorer sleep quality than controls (p &lt; 0.001). Omalizumab response was good in 29.5%, moderate in 38.6%, and limited in 31.9% of patients. Despite treatment, 32.9% reported no change in quality of life, while 35.7% had mild and 31.4% had moderate improvement. A history of atopic disease was present in 55.7% of patients, who had significantly higher daytime sleepiness scores than those without (p = 0.045). In CSU patients, while omalizumab improves symptoms and quality of life, psychological distress persists in substantial subsets, highlighting the need to address mental health and lifestyle factors.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00403-025-04231-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143845727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Abrocitinib as a novel therapeutic approach for refractory prurigo nodularis: real world evidence","authors":"Abdullah Demirbas,&nbsp;Esin Diremsizoglu,&nbsp;Gizem Cınar,&nbsp;Cigdem Vural","doi":"10.1007/s00403-025-04217-8","DOIUrl":"10.1007/s00403-025-04217-8","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143835555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hydroxychloroquine is safe and efficacious in oral lichen planus: data from a large outpatient cohort","authors":"Khava Abdusalamova,&nbsp;Margitta Worm,&nbsp;Farzan Solimani","doi":"10.1007/s00403-025-04226-7","DOIUrl":"10.1007/s00403-025-04226-7","url":null,"abstract":"<div><p>Lichen planus (LP) is a chronic inflammatory T-cell mediated disease affecting the skin, mucous membranes and skin appendages. Data on clinical phenotypes and systemic treatment of LP are limited. We analyzed a cohort of LP patients (equal or older than 18 years) regarding their clinical phenotypes (subtype, demographics, comorbidities) and treatment. Patients were selected from 2017 to 2023 who were seen in our outpatient clinic during a treatment period of at least 2 years. We identified 85 patients (62 females, 73% and 76 above 50 years; 89%) who met selection criteria. 33 had oral LP (39%), 23 had cutaneous LP (27%) and 2% had both or other manifestations (32%). Frequent comorbidities were hypertension (n = 40), hypothyroidism (n = 17), asthma (n = 11), diabetes (n = 10) and dyslipidemia (n = 8). 44% were taking a medication known to favor LP onset. 2/85 patients had a malignant transformation. 33 patients were treated topically and 50 required systemic therapy. Hydroxychloroquine (HCQ) (n = 18; 36%) and retinoids (n = 17; 34%) were the most commonly used systemic medications. Both were efficacious as determined by the investigator global response reaching rates 78% and 71%, respectively. The tolerability of retinoids was lower than HCQ (adverse event rate 29% versus 6%). Our results confirm previous data on clinical phenotypes and comorbidity patterns in LP patients. The treatment assessment suggests that HCQ may be an efficacious and safe first-line treatment for mucosal lichen planus. Further data from prospective controlled clinical trials are needed to prove the optimal treatment approach for different clinical phenotypes of LP.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00403-025-04226-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143830818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medicinal plants and their derivatives for skin and hair: a Mediterranean perspective of women care","authors":"Latifa Bouissane,&nbsp;Yahya Elfardi,&nbsp;Sohaib Khatib,&nbsp;Ahmed Fatimi,&nbsp;Carla Pereira,&nbsp;Natália Cruz-Martins","doi":"10.1007/s00403-025-04202-1","DOIUrl":"10.1007/s00403-025-04202-1","url":null,"abstract":"<div><p>Since olden days, medicinal and aromatic plants have been consumed due to their well-known therapeutic, ornamental, culinary, and cosmetic properties. Plant-based cosmetics comprise a growing market offering brands of sustainable products with the ultimate goal of responding to the woman needs to boost their natural beauty, such as soothing, toning, moisturizing and protecting skin and hair. The increasing focus on body and beauty care, combined with a better understanding of the diverse biological effects of plants and their derivatives, has revitalized their significance in aesthetic, cosmetic, and dermatological contexts. Concurrently, the increasing prevalence of allergies and hypersensitivity reactions to synthetic additives commonly found in cosmetics and other skin products has spurred interest in seeking healthier and more efficacious natural alternatives. An intense investigation has been stated around the formulation of medicinal plants- and other plant-based cosmetic products for dermatological and aesthetic purposes. Similarly, a raising awareness by cosmetics’ manufacturers and related industries have been progressively stated, culminating with the emergence of a line of plant-based cosmetics increasingly safe and with reliable quality features for multiple purposes. Although a high demand for natural-based products for cosmetic purposes has been stated, further studies are required to deepening knowledge on their beneficial properties, safety and quality features and to identify the main limitations and likelihood of side effects occurrence. In this review, an outlook of the current scenario regarding the use of medicinal and aromatic plants as cosmetic ingredients in the formulation of skin care and other dermatological products traditionally used by the Mediterranean woman for prevention and even cure of skin and hair diseases or for beautification is provided.</p><h3>Graphical abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00403-025-04202-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143824582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-in-kind 3D bioprinted human skin model using recombinant human collagen","authors":"Hemanth Gudapati,&nbsp;Rafaela Mayumi Simoes Torigoe,&nbsp;Aydin Tahmasebifar,&nbsp;K-Raman Purushothaman,&nbsp;Saranya Wyles","doi":"10.1007/s00403-025-04236-5","DOIUrl":"10.1007/s00403-025-04236-5","url":null,"abstract":"<div><p>Reliable translational human skin models are lacking for modeling skin diseases and screening effective therapeutics. 3D bioprinting is an emerging technology that enables the fabrication of human skin models that mimic the structure and functions of human skin in a dish (in-vitro). As a prototype, we present a first-in-kind fully humanized 3D bioprinted skin model as an alternative to animal testing for preclinical research. This model utilizes a plant-derived recombinant human collagen and human skin fibroblasts, melanocytes, and keratinocytes. The 3D bioprinted human skin model expresses involucrin and cytokeratin 14, contains melanin granules, and structurally resembles human skin. However, the morphology of keratinocytes is slightly different, containing a thicker layer of proliferative keratinocytes and a thinner layer of differentiated, cornified keratinocytes. Nevertheless, the model shows epidermal stratification, which indicates skin maturation. Further, the model lacks skin appendages such as hair follicles and sweat glands, as current bioprinting technology cannot deliver distinct cells at the single-cell resolution. Recent advances in 3D bioprinting such as spheroid-based bioprinting show potential to address these limitations. Hence, 3D bioprinting of skin using plant-derived recombinant human collagen, presents significant advantages, including high-throughput production of personalized human skin models, reduction of animal testing, and potential applications in regenerative medicine.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A split face study comparing intralesional tranexamic acid versus 1064 nm long pulsed Nd: YAG laser for acne vulgaris treatment","authors":"Heba Hussien Muhammad Eltanany,&nbsp;Faten Abdel Wadoud Abdel Qawy,&nbsp;Mervat Hamdino,&nbsp;Mona S. Ali","doi":"10.1007/s00403-025-04164-4","DOIUrl":"10.1007/s00403-025-04164-4","url":null,"abstract":"<div><p>Acne is among most prevalent skin conditions that adversely impacts patients’ quality of life and self-confidence. Conventional treatment methods face issues with high recurrence rates and unwanted side effects, prompting the need to explore new acceptable treatment options. Comparing the safety and clinical efficacy of intralesional tranexamic acid (TXA) versus 1064 nm long pulsed Nd:YAG laser in the treatment of facial inflammatory acne vulgaris. 30 patients with facial acne vulgaris were involved in a prospective randomized split-face comparative study. Each patient was treated with long-pulsed Nd: YAG laser on one side, and intralesional TXA on the other side at 2-week interval for 4 sessions. Cases were assessed through Investigator Global Assessment of acne (IGA) scale, lesions counting, and erythema score at baseline, after end of treatment, and after follow-up for 3 months. A statistically significant reduction in IGA, lesions count, and erythema score was found in both treated sides (p-value &lt; 0.001). Improvement of IGA and non-inflammatory lesions count was better in laser side more than TXA side after end of treatment and follow-up (p-value &lt; 0.05). Improvement of inflammatory lesions count was non-significant in both sides after end of treatment, while after follow-up it was better on laser side. Improvement of erythema score was non-significant between both therapy modalities after end of treatment and follow-up. 1064 nm long-pulsed Nd: YAG laser and intralesional TXA are effective, and safe treatment modalities for acne. However, Nd-YAG laser has prolonged therapeutic effect over intralesional TXA so, TXA can be considered a promising lunch-time procedure enhancing the outcome.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143824584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review on recent advances and challenges of microneedle technology for enhanced topical treatment of skin disorders","authors":"Hema,&nbsp;Anu Jindal,&nbsp;Rajni Bala,&nbsp;Amrinder singh","doi":"10.1007/s00403-025-04239-2","DOIUrl":"10.1007/s00403-025-04239-2","url":null,"abstract":"<div><p>Microneedles are tiny, minimally invasive needles that are made to create microchannels over a subcutaneous layer of the skin. These micro-injuries encourage the secretion of growth factors and prompt collagen synthesis. The reasons for using microneedling therapy have increased significantly, leading to its widespread adoption in dermatology. This review article discussed recent advances and challenges of microneedle technology for enhanced topical treatment of skin disorders. It discussed the effective and safe use of microneedles for treating different types of skin conditions like acne, scars, alopecia, melasma, skin rejuvenation, and photo-damage. The drug delivery through the skin was enhanced and rare or permanent adverse effects were not mentioned, while temporary redness and post-inflammatory hyperpigmentation were frequently seen. Microneedling seems to be a generally reliable and secure treatment choice for various skin conditions. More extensive and randomized clinical trials were necessary to ensure their safety and efficacy across diverse populations, conditions, and treatment durations. This trial helps to identify optimal dosages, long-term outcomes, and any adverse effects that may not appear in smaller studies. They also enable comparisons with existing therapies, ensuring the technology’s generalizability and value. Moreover, such trials are essential for regulatory approval and to determine which microneedle technologies work best for specific uses.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}